Difference between revisions of "Tremelimumab (Imjudo)"
m (Jwarner moved page Tremelimumab (ticilimumab) to Tremelimumab (Imjudo): FDA approval) |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | ||
| + | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Hepatocellular carcinoma]] | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Colorectal cancer]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' CP-675, CP-675206 | *'''Code name:''' CP-675, CP-675206 | ||
*'''Generic name:''' ticilimumab | *'''Generic name:''' ticilimumab | ||
| + | *'''Brand name:''' Imjudo | ||
==References== | ==References== | ||
| Line 18: | Line 27: | ||
[[Category:Anti-CTLA-4 antibodies]] | [[Category:Anti-CTLA-4 antibodies]] | ||
| − | [[Category:Colorectal cancer medications | + | [[Category:Colorectal cancer medications]] |
| + | [[Category:Hepatocellular carcinoma medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2022]] |
Revision as of 21:44, 24 October 2022
General information
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is established
Diseases for which it is used
History of changes in FDA indication
Also known as
- Code name: CP-675, CP-675206
- Generic name: ticilimumab
- Brand name: Imjudo